LAPIX-IO

N/A

Report date: 2026/03/17 20:00:15

NME

Base Information

Drug NameLAPIX-IO

Drug Alias NameN/A

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsProgrammed cell death protein 1 blockersHepatitis A virus cellular receptor 2 inhibitors +[4]

TargetsKiller cell lectin-like receptor subfamily G member 1Hepatitis A virus cellular receptor 2Programmed cell death protein 1 +[4]

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesLAPIX Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesLAPIX Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A